|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (5Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings (SCM21) being held virtually from April 6 – 10, 2021. For information about the virtual event, visit: https://www.kidney.org/spring-clinical.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
NEW YORK, NY / ACCESSWIRE / March 11, 2021 / DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 11, 2021 at 8:00 AM Eastern Time.